Source comparison
Sermorelin Dose Response Research: Clinical Trial Comparison
The table below compares findings from three major sermorelin dose-response studies, showing how GH response plateaus above 1mcg/kg across different populations. Thorner et al. (1996), JCEM Healthy men aged 21–42 0.3–3.0 mcg/kg 42 ng/mL at 1.0 mcg/kg; 48 ng/mL
This comparison does not assign a generated winner or score.
- The table below compares findings from three major sermorelin dose-response studies, showing how GH response plateaus above 1mcg/kg across different populations.
- Thorner et al. (1996), JCEM
- Healthy men aged 21–42
- 0.3–3.0 mcg/kg
- 42 ng/mL at 1.0 mcg/kg; 48 ng/mL at 3.0 mcg/kg
- 1.0 mcg/kg
- Doubling dose beyond 1 mcg/kg produced only 14% additional GH. Diminishing returns with increased side effects
- Walker et al. (2006), J Gerontology
- Men aged 55–65 with low IGF-1
- 0.5–2.0 mcg/kg
- 28 ng/mL at 1.5 mcg/kg; 30 ng/mL at 2.0 mcg/kg
- 1.5 mcg/kg
- Older adults required 50% higher dose to match younger cohort response. Age-related pituitary reserve determines ceiling
- Veldhuis et al. (2004), Am J Physiol
- Postmenopausal women
- 0.8–1.6 mcg/kg
- 35 ng/mL at 1.0 mcg/kg; 36 ng/mL at 1.6 mcg/kg
- Female response curve plateaus at same threshold as males. Sex differences minimal in GHRH receptor pharmacology